Home  >  Hybrimune™ - The Hybridoma Production System

	Hybrimune™ - The Hybridoma Production System

Introduction View Hybrimune™ Data Sheet (203 KB) View Cytofusion® Medium Data Sheet (102 KB)
The Hybrimune™ hybridoma production system is a large volume cell fusion system based on electrofusion technology. While Hybrimune™ usage varies in scope, the most notable applications are Monoclonal Antibody target discovery (MAB) and personal vaccine production by fusing a patient's immune cells with tumor cells (Tumor-DC Immunotherapy). Cyto Pulse's large intellectual property portfolio in cell fusion, including patents and patents pending, has enabled a considerable increase in fusion efficiency over pre-existing methods.
Hybrimune™ consists of three interdependent parts: the CEEF-50B waveform generator, large 2 ml and 9 ml coaxial fusion chambers, and low conductivity Cytofusion® Medium. It is operated by user interface software on a Windows® PC.

Technology Two cell types are placed in a chamber that produces non-uniform electric fields. Special non-linear amplitude alternating electric fields are used to align and compress the dissimilar cells. An electroporation pulse is then applied to fuse the cells. The special Cyto Pulse technology has proven to be greater than 8 to 100 times more efficient than cell fusion using polyethylene glycol for hybridoma production. The system includes one 2 ml optimization chamber with clear bottom so the cell alignment process can be observed. A 9 ml chamber is also provided for bulk processing after the optimization process is complete. Cyto Pulse Cytofusion® low conductivity medium is required.

Personal vaccination production - tumor cell/dendritic cell Arizona Cancer Center, IDM, Paris and Cyto Pulse conducted extensive research on personal vaccine production. The results were published on 26 March 2004 in Cancer Immunology, Immunotherapy. Arizona Cancer Center Study Results

DC-MCF-7

DC -A549

Hybridoma production for MAB Images on the right detail post-fusion hybridomas, courtesy of Medarex. Results of several comparison studies against PEG are presented in the below PDF. Medarex Study Results Morphotek Human Antibodies
Numerous commercial hybridoma production licenses for Monoclonal Antibody discovery are in place worldwide: Medarex, Princeton, NJ, USA Novo Nordisk, Denmark Genmab, Netherlands Morphotek, Exton, PA, USA NovImmune, Geneva, Switzerland Schering-Plough Biopharma (formerly DNAX Research, Inc.), USA Boehringer Ingelheim, Austria Genentech, Inc., San Francisco, CA, USA Mapp Biopharmaceutical, Inc., San Diego, CA, USA OncoMed Pharmaceuticals, Mountain View, CA, USA Amgen, Inc., USA Takeda Pharmaceutical, Osaka, Japan ZymoGenetics, Seattle, WA, USA MedImmune (formerly Cambridge Antibody Technology), Cambridge, UK Trellis Bioscience, Inc., South San Francisco, CA, USA Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA Genomics Institute of Novartis Research Foundation (GNF), San Diego, CA, USA Galaxy Biotech, Cupertino, CA, USA Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA Daiichi Sankyo Co., Ltd., Tokyo, Japan Centocor (J&J), Radnor, PA, USA Takeda San Francisco, San Francisco, CA, USA Organon Research, Schering-Plough, Cambridge, MA, USA 4-Antibody, Basel, Switzerland Others in negotiation This system is available under direct license agreement with Cyto Pulse. Please Contact Cyto Pulse for Additional Information Part No. 016-100543